SOPHiA GENETICS SA (SOPH)
Chart Events
Performance Outlook
| Previous Close | 4.9400 |
| Open | 5.0000 |
| Bid | 4.9100 x 1200 |
| Ask | 5.0000 x 2200 |
| Day's Range | 4.9000 - 5.0000 |
| 52 Week Range | 2.1600 - 19.8000 |
| Volume | |
| Avg. Volume | 99,648 |
| Market Cap | 312.902M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2250 |
| Earnings Date | Sep 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- Motley Fool
Sophia Genetics SA (SOPH) Q2 2022 Earnings Call Transcript
My name is Jennifer Pottage, and I'm the head of investor relations at SOPHiA GENETICS. Joining me today are Dr. Jurgi Camblong, our co-founder and chief executive officer; and Ross Muken, our chief financial officer.
- Zacks
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 0% and 0.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022
Steady Operational Performance Amidst Macroeconomic HeadwindsBOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Revenue for the second quarter of 2022 was $11.7 million, representing year-over-year growth of 15%; constant currency revenue growth excluding COVID-19-related revenues was 36%Gross m
